Perspective Therapeutics (NYSE:CATX) Trading Down 6.3% – What’s Next?

Perspective Therapeutics, Inc. (NYSE:CATX) shares traded down 6.3% during trading on Wednesday . The stock traded as low as $10.00 and last traded at $10.00. 316,149 shares traded hands during trading, a decline of 54% from the average session volume of 682,426 shares. The stock had previously closed at $10.67.

Analysts Set New Price Targets

CATX has been the subject of several research analyst reports. Royal Bank of Canada lowered their price objective on Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating for the company in a research report on Friday, August 16th. Truist Financial started coverage on Perspective Therapeutics in a research note on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price objective on the stock. Wedbush reissued an “outperform” rating and set a $20.00 target price on shares of Perspective Therapeutics in a report on Thursday, October 24th. Oppenheimer reaffirmed an “outperform” rating and issued a $22.00 price target on shares of Perspective Therapeutics in a report on Friday, October 11th. Finally, Bank of America initiated coverage on shares of Perspective Therapeutics in a research report on Thursday, July 25th. They set a “buy” rating and a $24.00 price target for the company. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat, Perspective Therapeutics currently has a consensus rating of “Buy” and an average price target of $20.63.

Perspective Therapeutics Stock Performance

The business’s fifty day simple moving average is $12.93.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.04. The business had revenue of $0.53 million during the quarter. Analysts predict that Perspective Therapeutics, Inc. will post -0.87 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Bleakley Financial Group LLC acquired a new stake in Perspective Therapeutics during the 1st quarter worth $40,000. Vanguard Group Inc. grew its position in Perspective Therapeutics by 34.6% during the 1st quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock worth $21,158,000 after purchasing an additional 4,566,356 shares during the last quarter. Affinity Asset Advisors LLC purchased a new position in Perspective Therapeutics during the 1st quarter worth $6,069,000. Janus Henderson Group PLC purchased a new position in Perspective Therapeutics during the 1st quarter worth $15,511,000. Finally, Virtu Financial LLC purchased a new position in Perspective Therapeutics during the 1st quarter worth $138,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.